General MedicationsORALGeneric
PALBOCICLIB
PALBOCICLIB
Standard Dose
75MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview PALBOCICLIB is listed in Drugs@FDA under application 214758 (ANDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient PALBOCICLIB Form and strength CAPSULE;ORAL - 75MG Sponsor MSN PHARMACEUTICALS INC Submission history Latest submission status date: 2023-04-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview PALBOCICLIB is listed in Drugs@FDA under application 214758 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient PALBOCICLIB Form and strength CAPSULE;ORAL - 75MG Sponsor MSN PHARMACEUTICALS INC Submission history Latest submission status date: 2023-04-12 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.